Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 139-148

  Zampino, M G ^a   Magni, E ^a   Santoro, L ^a   Zorzino, L ^a   Dell'Orto, P ^a   Sonzogni, A ^a   Fazio, N ^a   Monfardini, L ^a   Chiappa, A ^a   Biffi, R ^a   De Braud, F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Advanced colorectal cancer; Chemotherapy; Gefitinib; Serum EGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; OXALIPLATIN; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 53149090907     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0722-x     Document Type: Article

References (36)

1. J Albanell F Rojo J Baselga 2001 Pharmacodynamic studied with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 Sem Oncol 28 5 Suppl 16 56 66
2. AT Baron JM Lafky C Boardman 1999 Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 8 2 129 137
3. Cappuzzo F, Finocchiaro G, Rossi E et al (2007) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. Oct 31
4. F Cappuzzo V Gregorc E Rossi 2003 Gefitinib in pre-treated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC J Clin Oncol 21 14 2658 2663
5. F Ciardiello R Caputo R Bianco 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cencer cells by GEFITINIB (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 2053 2063
6. H Cortes-Funes H Soto Parra 2003 Extensive experiences of disease control with gefitinib and the role of prognostic markers Br J Cancer 89 S3 S8
7. DR Cox 1972 Regression models and life-tables (with discussion) J R Stat Soc B 34 187 220
8. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345
9. SJ Decker 1989 Epidermal growth factor induced truncation of the epidermal growth factor receptor J Biol Chem 264 17641 17644
10. M Fukuoka S Yano G Giaccone 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Final results from a phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1) J Clin Oncol 21 2237 2246
11. G Giaccone RS Herbst C Manegold 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784
12. V Gregorc GL Ceresoli I Floriani 2004 Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer Clin Cancer Res 10 6006 6012
13. Harrell FEJ (2001) Regression modelling strategies. Springer, New York
14. RS Herbst G Giaccone JH Schiller 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794
15. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression (Wiley Series in probability and statistics), 2nd edn. Wiley, New York
16. S Khambata-Ford CR Garrett NJ Meropol 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 22 3230 3237
17. T Kuo GA Fisher 2005 Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer Clin Colorectal Cancer 5 Suppl 2 S62 S70
18. A Lievre JB Bachet V Boige 2008 KRAS mutations as an indipendent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 3 374 379
19. J Loeffler-Ragg S Skvortsov B Sarg 2005 Gefitinib-responsive EGFR-positive colorectal cancer have different proteome profiles from non-responsive cell lines Eur J Cancer 41 2338 2346
20. TJ Lynch DW Bell R Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 29 39
21. N Magne JL Fishel A Dubreuil 2002 Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathways status of tumor cells on the antiproliferative effect of ZD1839 ("Iressa") Br J Cancer 86 9 1518 1523
22. A Mayer M Takimoto E Fritz G Schellander K Kofler H Ludwig 1993 The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal Cancer 71 2454 2460
23. R Peto MC Pike P Armitage 1977 Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples Br J Cancer 35 1 39
24. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor J Clin Oncol 22 1201 1208
25. A Sartore-Bianchi M Moroni S Veronese 2007 Epidermal Growth factor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 22 3238 3245
26. M Scartozzi I Bearzi C Pierantoni 2007 Nuclear factor-kB tumor regression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy J Clin Oncol 25 3930 3935
27. FM Sirotnak 2003 Studies with ZD1839 in preclinical model Sem Oncol 30 12 20
28. FM Sirotnak MF Zakowski VA Miller HI Scher MG Kris 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 12 4885 4892
29. C Souder K Leitzel SM Ali 2006 Serum epidermal growth factor receptor/HER2 predicts poor survival in patients with metastatic breast cancer Cancer 107 2337 2345
30. D Soulieres NN Senzer EE Vokes M Hidalgo SS Agarwala LL Siu 2004 Multicenter phase II study of Erlotinib, an oral epidermal growth factor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of head and neck J Clin Oncol 22 77 85
31. A Ulrich J Schlessinger 1990 Signal transduction by receptors with tyrosine kinase activity Cell 61 203 212
32. E Van Cutsem M Peeters S Siena 2007 Open label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer J Clin Oncol 25 1658 1664
33. Van Cutsem E, Yumblet Y, Gelderblom H et al (2007) Cetuximab dose escalation study in patients with metastatic colorectal slight skin reactions on cetuximab standard dose treatment (EVEREST) data of randomized study), Meeting ASCO 2007 (Abstr 237)
34. AE Wakeling SP Guy JR Woodburn 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy Cancer Res 6 2053 2063
35. MG Zampino E Magni C Massaccesi 2007 First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer Cancer 110 4 752 758
36. Zampino MG, Magni E, Zorzino L et al (2007) Epidermal growth factor receptor (EGFR) serum level may predict response in patients with advanced colorectal cancer (ACC) treated with gefitinib. J Clin Oncol 2007 ASCO Annual Meeting Proceedings part I. vol 25, No. 18S (June 20 Suppl):4119